Humana (NYSE:HUM) Price Target Cut to $250.00 by Analysts at Deutsche Bank Aktiengesellschaft

Humana (NYSE:HUM) had its price objective lowered by Deutsche Bank Aktiengesellschaft from $349.00 to $250.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has a hold rating on the insurance provider’s stock.

Several other equities research analysts also recently commented on HUM. Oppenheimer decreased their target price on shares of Humana from $400.00 to $280.00 and set an outperform rating for the company in a research report on Thursday. JPMorgan Chase & Co. boosted their price objective on Humana from $332.00 to $396.00 and gave the stock a neutral rating in a report on Wednesday, August 21st. Cantor Fitzgerald reaffirmed a neutral rating and set a $395.00 target price on shares of Humana in a research report on Tuesday. Morgan Stanley initiated coverage on Humana in a research note on Monday, June 24th. They set an equal weight rating and a $374.00 price objective on the stock. Finally, Leerink Partners lowered Humana from an outperform rating to a market perform rating and reduced their target price for the company from $400.00 to $250.00 in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Hold and an average price target of $360.86.

Humana Price Performance

Shares of NYSE HUM opened at $241.72 on Thursday. The firm has a market capitalization of $29.13 billion, a P/E ratio of 15.05, a P/E/G ratio of 2.44 and a beta of 0.50. The firm’s 50-day moving average price is $340.75 and its 200-day moving average price is $342.90. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana has a 1-year low of $213.31 and a 1-year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the firm posted $8.94 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities research analysts anticipate that Humana will post 16.01 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.46%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Hantz Financial Services Inc. purchased a new stake in Humana during the second quarter valued at about $35,000. Family Firm Inc. bought a new stake in Humana during the second quarter worth about $37,000. Hollencrest Capital Management purchased a new position in shares of Humana in the 2nd quarter worth about $40,000. Finally, Riverview Trust Co purchased a new position in shares of Humana in the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.